Physician profile
Ranganathan N Ram
NPI 1003846163
$201,839.93
in general payments reported to CMS, 2019-2025
22 companies · $17.79 in 2025
The $17.79 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140K · 2020: $18K · 2021: $43K · 2023: $131 · 2024: $152 · 2025: $17.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $164,775.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $34,561.83 | 2019-2024 | Spravato |
| Bausch Health US, LLC | $590.60 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $329.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $317.17 | 2019-2021 | |
| Lundbeck LLC | $209.85 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.81 | 2019-2021 | |
| Axsome Therapeutics, INC. | $127.79 | 2023-2025 | Auvelity |
| Alkermes, INC. | $120.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $87.00 | 2019-2020 | |
| Neos Therapeutics, LP | $85.93 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $76.44 | 2019-2020 | |
| Adlon Therapeutics L.P. | $72.14 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.55 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $62.44 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $59.35 | 2019-2020 | |
| Eisai INC. | $41.57 | 2020 | |
| Abbvie INC. | $35.30 | 2021 | |
| Allergan, INC. | $31.05 | 2019 | |
| Neurocrine Biosciences, INC. | $18.90 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.12 | 2019 | |
| Shire North American Group INC | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranganathan Ram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.